# US 2015/0105271 A1 · Biomarkers for increased risk of drug-induced acute hypersensitivity syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105271 A1
- Document ID: US20150105271A1
- Status: Published application
- Kind: A1
- Application number: 14/512,370
- Filed: 2014-10-10
- Published: 2015-04-16
- Earliest claimed: 2013-10-10
- Assignees: Severe Adverse Event (Sae) Consortium
- Applicants: Severe Adverse Event (SAE) Consortium
- Inventors: Aris FLORATOS
- Web page: https://patentgrep.com/patent/US20150105271A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure provides a method for predicting the risk of a patient for developing adverse drug reactions, particularly drug-induced acute hypersensitivity syndrome (AHSS). The disclosure also provides a method of identifying a subject afflicted with, or at risk of, developing AHSS. In some aspects, the methods comprise analyzing at least one genetic marker, wherein the presence of the at least one genetic marker indicates that the subject is afflicted with, or at risk of, developing AHSS.

## Claims

### Claim 1

A method of identifying a subject afflicted with, or at risk of, developing acute hypersensitivity syndrome (AHSS), the method comprising:
(a) obtaining a nucleic acid-containing sample from the subject; and
(b) analyzing the sample to detect the presence of at least one genetic marker, wherein the presence of the at least one genetic marker indicates that the subject is afflicted with, or at risk of, developing AHSS.

### Claim 2 (depends on 1)

The method of claim 1, wherein the genetic marker is any of alleles, microsatellites, SNPs, or haplotypes.
